Iterum Therapeutics plc (ITRM)

Popular pages

• Our Company :: Iterum Therapeutics plc (ITRM)

  Company Summary Iterum Therapeutics plc: Headquartered in Dublin, Ireland, we are a clinical-stage pharmaceutical company dedicated to developing significantly differentiated anti-infectives aimed at ...

• Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of

  ™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades --Company to Host Conference Call on Monday, October 28 th at 8:30 a.m...

• Our Promise :: Iterum Therapeutics plc (ITRM)

  Responding to medical need Iterum was founded with one over-arching goal: to develop an antibiotic that addresses the growing crisis of multi-drug-resistant pathogens and meets the specific needs of p...

• Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral

  April 29, 2024 --First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024-- DUBLIN, Ireland and CHICAGO, April 29, 2024 ...

• Iterum Therapeutics Announces Positive Topline Results from its Phase 3 REASSURE Clinical Trial of

  Resistant Enterobacterales) Phase 3 clinical trial comparing oral sulopenem (sulopenem etzadroxil combined with probenecid in a bilayer tablet) to oral Augmentin ® (amoxicillin/clavulanate) in adult ...

• Press Releases :: Iterum Therapeutics plc (ITRM)

  2016 Oct 28, 2024